|
May 1
|
Prothena to Report First Quarter 2024 Financial Results on May 8
|
|
Apr 25
|
Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
|
|
Apr 15
|
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
|
|
Mar 28
|
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
|
|
Mar 26
|
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
|
|
Mar 5
|
Prothena to Participate in Upcoming Healthcare Conferences
|
|
Mar 4
|
Prothena Appoints David Ford to Newly Created Chief People Officer Position
|
|
Feb 17
|
Prothena Full Year 2023 Earnings: Beats Expectations
|
|
Feb 16
|
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
|
|
Feb 16
|
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript
|
|
Feb 15
|
Prothena Corp PLC (PRTA) Reports 2023 Financial Results and Provides 2024 Outlook
|
|
Feb 15
|
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
|
|
Jan 10
|
Prothena's (PRTA) Update on Pipeline Progress Disappoints
|
|
Jan 10
|
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
|
|
Jan 8
|
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
|
|
Dec 21
|
Prothena Corp PLC Chief Accounting Officer Sells Company Shares
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 3
|
Prothena (NASDAQ:PRTA) shareholder returns have been strong, earning 207% in 5 years
|
|
Dec 1
|
Insider Sell Alert: Karin Walker of Prothena Corp PLC Cashes Out 5,000 Shares
|
|
Aug 4
|
Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates
|